At the American College of Cardiology (ACC) Annual Scientific Session & Expo 2026, a systematic review and meta-analysis of sotatercept in pulmonary arterial hypertension (PAH) pooled data from 605 patients to characterize the therapy’s overall impact on hemodynamics, functional capacity, and cardiac stress markers. The analysis provides a more integrated view of sotatercept’s effect than any single trial and helps clarify its role alongside established vasodilator-based regimens.
PAH remains a progressive disease with high morbidity and mortality, as current treatments focus on vasodilation and symptom relief rather than reversing vascular remodeling and right ventricular overload. Against this backdrop, the central question is whether sotatercept delivers changes that are…